• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

HCV launch

The launch will most likely not happen. FDA still remembers the Norvir price hike and have had a negative attitude towards Abbott/Abbvie since then. I like selling moderiba in that it really is not a job and I just collect a paycheck. Just being candid folks!
 








The launch will most likely not happen. FDA still remembers the Norvir price hike and have had a negative attitude towards Abbott/Abbvie since then. I like selling moderiba in that it really is not a job and I just collect a paycheck. Just being candid folks!

You are definitely not an Abbvie employee or you are on another planet. The FDA has no concerns or jurisdiction over pricing of drugs. They also cannot prevent a drug from being launched that has solid efficacy and safety data. Harvoni has no clinical advantage over 3D. I would also say that the whole one pill QD is overblown. Firstly, the HCV population is generally highly motivated and a one pill regimen will impact adherence very little, if at all. Second, Docs will not prescribe the meds to patients who are in the midst of drug abuse or have other psychosocial issues that would impact adherence. Payors will also not approve the meds for those who are using drugs (all payors are requiring negative drug screens and at least 3 months clean from drugs).

3D has numerous clinical advantages over Harvoni: better in GT 1b (100% SVR), better cirrhotic data (larger numbers and more reliable data), lower failure rate in treatment experienced patients (Sapphire-2 vs. Ion-2), Harvoni cannot be used in pts with GFRs < 30, no Omeprazole > 20mg with Harvoni (at least 40% of patients in GI offices are on 40mg), solid co-infection and post transplant data.
 












You must be I lifer at Abbvie. What you said is accurate but incomplete. What part of anemia induced by RIBA is in your sales message? Hey cool aid. HCV market has changed payers are staging patients volume is down. Good luck
 




You are definitely not an Abbvie employee or you are on another planet. The FDA has no concerns or jurisdiction over pricing of drugs. They also cannot prevent a drug from being launched that has solid efficacy and safety data. Harvoni has no clinical advantage over 3D. I would also say that the whole one pill QD is overblown. Firstly, the HCV population is generally highly motivated and a one pill regimen will impact adherence very little, if at all. Second, Docs will not prescribe the meds to patients who are in the midst of drug abuse or have other psychosocial issues that would impact adherence. Payors will also not approve the meds for those who are using drugs (all payors are requiring negative drug screens and at least 3 months clean from drugs).

3D has numerous clinical advantages over Harvoni: better in GT 1b (100% SVR), better cirrhotic data (larger numbers and more reliable data), lower failure rate in treatment experienced patients (Sapphire-2 vs. Ion-2), Harvoni cannot be used in pts with GFRs < 30, no Omeprazole > 20mg with Harvoni (at least 40% of patients in GI offices are on 40mg), solid co-infection and post transplant data.

OMG! Name one HCV Opinion Leader that supports 3D over Harvoni!!! Drinking too much kool aid my friend, Louie Louie!
 












You must be I lifer at Abbvie. What you said is accurate but incomplete. What part of anemia induced by RIBA is in your sales message? Hey cool aid. HCV market has changed payers are staging patients volume is down. Good luck

Only 6% of patients experienced anemia across the Phase 3 program (2,300 patients). It's really not a big deal and easily managed with RBV dose reduction.
 












Only 6% of patients experienced anemia across the Phase 3 program (2,300 patients). It's really not a big deal and easily managed with RBV dose reduction.

You want to claim efficacy adv in cirrhosis patients and you think that patient type will only have 6% anemia. You silly abbvie lifer. You are going to do great
 




























You want to claim efficacy adv in cirrhosis patients and you think that patient type will only have 6% anemia. You silly abbvie lifer. You are going to do great

Dude, in Turquoise-2 anemia was a bit higher at 9% but no one d/c'd because of it. And guess what? Gilead is now recommending (off label) the use of RBV in their treatment experienced cirrhotics so they can cut the regimen down from 24 weeks to 12 weeks. I guess RBV isn't so bad after all.